Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.
Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B; ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators. Van Gorp T, et al. Among authors: hanker lc. Ann Oncol. 2024 Nov;35(11):968-980. doi: 10.1016/j.annonc.2024.08.2242. Epub 2024 Sep 14. Ann Oncol. 2024. PMID: 39284383 Free article. Clinical Trial.
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. Mirza MR, et al. Among authors: hanker lc. Future Oncol. 2024 Jul 11:1-18. doi: 10.2217/fon-2023-0940. Online ahead of print. Future Oncol. 2024. PMID: 38990090
Sorangicin A Is Active against Chlamydia in Cell Culture, Explanted Fallopian Tubes, and Topical In Vivo Treatment.
Graspeuntner S, Koethke K, Scholz C, Semmler L, Lupatsii M, Kirchhoff L, Herrmann J, Rox K, Wittstein K, Käding N, Hanker LC, Stadler M, Brönstrup M, Müller R, Shima K, Rupp J. Graspeuntner S, et al. Among authors: hanker lc. Antibiotics (Basel). 2023 Apr 22;12(5):795. doi: 10.3390/antibiotics12050795. Antibiotics (Basel). 2023. PMID: 37237698 Free PMC article.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. Among authors: hanker lc. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients.
Proppe L, Jagomast T, Beume S, Klapper L, Gitas G, Köster F, Perner S, Rody A, Ribbat-Idel J, Hanker LC. Proppe L, et al. Among authors: hanker lc. J Cancer Res Clin Oncol. 2023 Aug;149(10):7155-7164. doi: 10.1007/s00432-023-04632-2. Epub 2023 Mar 8. J Cancer Res Clin Oncol. 2023. PMID: 36884115 Free PMC article.
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial.
Grünwald V, Pink D, Egerer G, Schalk E, Augustin M, Deinzer CKW, Kob V, Reichert D, Kebenko M, Brandl S, Hahn D, Lindner LH, Hoiczyk M, Ringsdorf U, Hanker LC, Hempel D, De Rivas B, Wismann T, Ivanyi P. Grünwald V, et al. Among authors: hanker lc. Cancers (Basel). 2022 Oct 25;14(21):5234. doi: 10.3390/cancers14215234. Cancers (Basel). 2022. PMID: 36358652 Free PMC article.
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Lück HJ, Emons G, Meier W, Gropp-Meier M, Schröder W, de Gregorio N, Hilpert F, Harter P. Pfisterer J, et al. Among authors: hanker lc. J Clin Oncol. 2023 Feb 1;41(4):893-902. doi: 10.1200/JCO.22.01010. Epub 2022 Nov 4. J Clin Oncol. 2023. PMID: 36332161 Clinical Trial.
30 results